Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole.

ABSTRACT:

Purpose

To assess the effect of an intravitreal ocriplasmin injection on visual function, measured using visual acuity (VA) and vision-related quality of life.

Methods

Post hoc analysis of prespecified secondary end-points in two multicentre, randomized, double-masked, phase 3 clinical trials. A total of 652 participants with symptomatic vitreomacular adhesion were enrolled, of whom 464 received a single intravitreal injection of 125 μg ocriplasmin and 188 received a single intravitreal placebo injection. Based on principal components analysis results, visual function response (VFR) was defined as either a VA improvement of ≥2 lines; or an improvement in the composite score of the National Eye Institute Visual Function Questionnaire (VFQ-25) exceeding the minimal clinically

SUBMITTER: Jackson TL 

PROVIDER: S-EPMC5901404 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature